Source: International Congress 2016 – An update on pleural empyema diagnostics and treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Philippe Astoul (Marseille, France). How to prevent progression to stage III disease. International Congress 2016 – An update on pleural empyema diagnostics and treatment

Member's Comments

No comment yet.

Related content which might interest you: Empyema: How to prevent progression to stage III disease Source: ERS Course 2019 - Thoracoscopy and Pleural Techniques Year: 2019 Empyema: How to prevent progression to stage III disease Source: ERS Course 2019 - Thoracoscopy and Pleural Techniques, April 2019 Year: 2019 Empyema: How to prevent progression to stage III disease Source: ERS Skills Course 2018 - Thoracoscopy and pleural techniques Year: 2018 NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Heterogeneity of stage III and its implication on treatment Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 How to manage a patient with COPD - early identification and how to prevent progression Source: ERS Satellites 2021 Year: 2021 Interleukine-17A implicated in survival outcome of patients with late stage lung adenocarcinoma Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Relation of various parameters to the survival rate in stage 0 to stage IIa chronic obstructive pulmonary disease (COPD) according to the GOLD guidelines Source: Eur Respir J 2003; 22: Suppl. 45, 578s Year: 2003 Managing end stage disease in ILDs Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Managing end stage disease in ILDs Source: ERS Course 2016 Year: 2016 Specific pattern of growth factor gene expression in stage I versus stage II/III sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 213s Year: 2002 Stage IV sarcoidosis: comparison of survival with the general population and causes of death Source: Eur Respir J 2011; 38: 1368-1373 Year: 2011 Time lost for diagnostics of lung carcinoma related to disease stage and prognosis Source: Eur Respir J 2004; 24: Suppl. 48, 297s Year: 2004 Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 A new paradigm for classification of disease severity and progression of COPD Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012 Systemic inflamation and prognosis in lung cancer stage I-II Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012 Evaluating the effects of pulmonary rehabilitation in patients with COPD in early and late disease stages. Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients Year: 2008